Clinical Trials

Phase II Trial of Zanzalintinib (XL-092) in Combination with Durvalumab plus Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

Cancer Type

Liver

ClinicalTrials.gov Identifier

NCT06698250

Principal Investigator

Sukeshi Patel Arora, MD

For more information about this study
View Details

About This Study

Phase II trial evaluating the combination of XL-092 with durvalumab and tremelimumab in unresectable HCC. This phase II trial design will be preceded by a safety lead in of 9-12 patients.